Exelixis

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Exelixis 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About EXEL

Exelixis, Inc. is an oncology company, which focuses on discovering, developing, and commercialization of new medicines for difficult-to-treat cancers. Its products include cabometyx, cometriq, and cotellic. 

CEO
Michael M. Morrissey
CEOMichael M. Morrissey
Employees
1,077
Employees1,077
Headquarters
Alameda, California
HeadquartersAlameda, California
Founded
1994
Founded1994
Employees
1,077
Employees1,077

EXEL Key Statistics

Market cap
13.32B
Market cap13.32B
Price-Earnings ratio
17.56
Price-Earnings ratio17.56
Dividend yield
Dividend yield
Average volume
2.57M
Average volume2.57M
High today
$53.28
High today$53.28
Low today
$52.01
Low today$52.01
Open price
$52.53
Open price$52.53
Volume
1.75M
Volume1.75M
52 Week high
$53.28
52 Week high$53.28
52 Week low
$33.76
52 Week low$33.76

Stock Snapshot

The current Exelixis(EXEL) stock price is $52.99, with a market capitalization of 13.32B. The stock trades at a price-to-earnings (P/E) ratio of 17.56.

During the trading session on 2026-06-10, Exelixis(EXEL) shares reached a daily high of $53.28 and a low of $52.01. At a current price of $52.99, the stock is +1.9% higher than the low and still -0.5% under the high.

Trading volume for Exelixis(EXEL) stock has reached 1.75M, versus its average volume of 2.57M.

Over the past 52 weeks, Exelixis(EXEL) stock has traded between a high of $53.28 and a low of $33.76.

Over the past 52 weeks, Exelixis(EXEL) stock has traded between a high of $53.28 and a low of $33.76.

EXEL News

Investing.com 18h
Exelixis stock hits all-time high at 52.98 USD - Investing.com

...

Exelixis stock hits all-time high at 52.98 USD - Investing.com
Simply Wall St 3d
How Broad CABOMETYX PFS Benefit At Exelixis Has Changed Its Investment Story

Exelixis recently reported subgroup results from the phase 3 CABINET trial showing that CABOMETYX significantly improved progression-free survival versus placeb...

How Broad CABOMETYX PFS Benefit At Exelixis Has Changed Its Investment Story

Analyst ratings

45%

of 20 ratings
Buy
45%
Hold
45%
Sell
10%

People also own

Based on the portfolios of people who own EXEL. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.